Services-Medical Laboratories · SIC 8071

QUEST DIAGNOSTICS INC

DGX

Watch

Latest revenue

$2.90B

as of 2026-03-31

Latest net income

$252.0M

as of 2026-03-31

Net margin

8.7%

as of 2026-03-31

Price · 5Y

+10.4% / yr 3.4 pts / yr vs S&P 500 63.5% total
Compare:

Live market

delayed ≤15 min
$195.21
0.72%
Market cap
$21.61B
Enterprise value
$27.68B
P/E (trailing)
21.8×
Forward P/E
P/B
2.93×
Dividend yield
1.7%
52-wk high
$213.50
52-wk low
$164.65
Beta
Shares out
110.7M

5-year trend

About DGX

Business description and risk factors will appear here once DGX's latest filing is fully ingested.

Profitability

Operating margin

14.1%

3.4%

Net margin

9.0%

1.9%

Return on equity

13.8%

7.7%

Return on assets

6.1%

13.4%

Leverage

Debt / equity

1.26×

8.7%

Long-term debt / equity

0.72×

13.0%

Debt / assets

55.8%

3.8%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$2.90B+9.2%$252.0M+14.5%8.7%

Q4 2025

2025-12-31

$2.81B+7.1%$245.0M+10.4%8.7%

Q3 2025

2025-09-30

$2.82B+13.2%$245.0M+8.4%8.7%

Q2 2025

2025-06-30

$2.76B+15.2%$282.0M+23.1%10.2%

Q1 2025

2025-03-31

$2.65B+12.1%$220.0M+13.4%8.3%

Q4 2024

2024-12-31

$2.62B$222.0M8.5%

Q3 2024

2024-09-30

$2.49B+8.4%$226.0M+0.4%9.1%

Q2 2024

2024-06-30

$2.40B+2.5%$229.0M-2.6%9.6%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Services-Medical Laboratories · SIC 8071

Your notes

Keep private notes on DGX — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$0

Insider selling

$35.0M

Net activity

−$35.0M

Distinct insiders

8

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue
2026-03-05

Catherine T. Doherty

EVP, Regional Businesses

Sale5,558$206.21$1.1M
2026-03-05

Michael E Prevoznik

SVP & General Counsel

Sale3,878$206.21$799.7K
2026-03-05

Patrick Plewman

SVP for Diagnostic Services

Sale2,855$206.21$588.7K
2026-03-04

Karthik Kuppusamy

SVP, Clinical Solutions

Sale2,628$204.86$538.4K
2026-03-03

Catherine T. Doherty

EVP, Regional Businesses

Sale632$207.73$131.3K
2026-03-03

Michael E Prevoznik

SVP & General Counsel

Sale526$207.73$109.3K
2026-03-03

Patrick Plewman

SVP for Diagnostic Services

Sale410$207.73$85.2K
2026-03-02

E. J. Davis

CEO and President

Sale10,000$212.52$2.1M

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns DGX

No institutional holdings on file for DGX yet.

Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).

Top questions investors are asking

Coming once DGX's latest filing finishes processing.